Etaracizumab, formerly designated as MEDI523 and then LM609, represents a unique method in antibody-mediated therapy. This humanized protein is intended to specifically inhibit the activity of complement factor , a critical component of the cascade involved in tissue damage. Data have investigated its possible use in different inflammatory dise… Read More